Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 8;10(9):54.
doi: 10.3390/medicines10090054.

Anticonvulsant Properties of 1-Diethylamino-3-phenylprop-2-en-1-one

Swagatika Das  1 , Praveen K Roayapalley  1 , Sarvesh C Vashishtha  1 , Umashankar Das  1 , Jonathan R Dimmock  1
Affiliations

Anticonvulsant Properties of 1-Diethylamino-3-phenylprop-2-en-1-one

Swagatika Das et al. Medicines (Basel). .

Abstract

There is a need for novel antiepileptic agents whose modes of action differ from those of current antiepileptic drugs. The objective of this study was to determine whether 1-diethylamino-3-phenylprop-2-en-1-one (2) could prevent or at least diminish convulsions caused by different mechanisms. This amide afforded protection in the maximal electroshock and subcutaneous pentylenetetrazole screens when given intraperitoneally to both mice and rats. A number of specialized tests in mice were conducted and are explained in the text. They revealed (2) to have efficacy in the 6 Hz psychomotor seizure test, the corneal kindling model, the mouse temporal epilepsy screen and a peripheral neuronal transmission test using formalin. Three screens in rats were undertaken, which revealed that (2) blocked chloride channels, inhibited peripheral neuronal transmission (tested using sciatic ligation and von Frey fibres) and afforded protection in the lamotrigine-resistant kindled rat model. The biodata generated reveal that (2) is an important lead molecule in the quest for novel structures to combat epilepsy.

Keywords: anticonvulsant; anticonvulsant screens; antiepileptic; convulsant; neurotoxicity; seizures.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflict of interest arising from this article.

Figures

Figure 1
Figure 1
Structures of the amides in series (1) and (2).
See this image and copyright information in PMC

References

    1. Riva A., Golda A., Balagura G., Amadori E., Vari M.S., Piccolo G., Iacomino M., Lat-tanzi S., Salpietro V., Minetti C., et al. New Trends and Most Promising Therapeutic Strategies for Epilepsy Treatment. Front. Neurol. 2021;12:753753. doi: 10.3389/fneur.2021.753753. - DOI - PMC - PubMed
    1. Löscher W., Potschka H., Sisodiya S.M., Vezzani A. Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options. Pharmacol. Rev. 2020;72:606–638. doi: 10.1124/pr.120.019539. - DOI - PMC - PubMed
    1. Grover G., Pal R., Bhatia R., Yar M.S., Nath R., Singh S., Raj K., Kumar B., Akhtar M.J. Design, synthesis, and pharmacological evaluation of aryl oxadiazole linked 1,2,4-triazine derivatives as anticonvulsant agents. Med. Chem. Res. 2022;31:781–793. doi: 10.1007/s00044-022-02880-4. - DOI
    1. Sahu M., Siddiqui N., Naim M., Alam O., Shahar Yar M., Sharma V., Wakode S. Design, Synthesis, and Docking Study of Pyrimidine-Triazine Hybrids for GABA Estimation in Animal Epilepsy Models: Pyrimidine-Triazine Hybrids as Anticonvulsants. Arch. Pharm. 2017;350:1700146. doi: 10.1002/ardp.201700146. - DOI - PubMed
    1. Dimmock J.R., Gunda S.G.R., Vashishtha S.C., Zello G.A., Das U., Nienaber K.H., Stables J.P., Allen T.M., Santos C.L. Anticonvulsants containing the N-(3-aryl-2-propenyl)amido pharmacophore. J. Enz. Inhib. Med. Chem. 2004;19:303–312. doi: 10.1080/14756360409162442. - DOI - PubMed

LinkOut - more resources